FARXIGA in Nephrology

CKD Patients at Risk of Progression with or without T2D

NEW INDICATION: The first therapy approved in 20 years to help delay the worsening of CKD in patients at risk of progression, with and without T2D.1

Protect life: FARXIGA is proven to help protect your patients with CKD at risk of progression against worsening kidney function, ESKD, CV death, and hospitalization for heart failure—so they can live life.1

IN PATIENTS WITH CKD AT RISK OF PROGRESSION, WITH OR WITHOUT T2D

FARXIGA complements ACEI/ARB therapy to help provide additional kidney protection1

FARXIGA provides a novel pathway for the treatment of CKD.1

  • FARXIGA reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may drive a feedback mechanism in the kidney, which decreases intraglomerular pressure

FARXIGA Complements ACEI/ARB Therapy to Help Provide Additional Kidney ProtectionFARXIGA Complements ACEI/ARB Therapy to Help Provide Additional Kidney Protection

The kidney protection seen in DAPA-CKD was independent of glucose lowering as it was seen in patients with and without T2D2


ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; DAPA-CKD=Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease; ESKD=end-stage kidney disease; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION FOR FARXIGA